Mifamurtide sodium 米伐木肽钠盐; MTP-PE sodium; L-MTP-PE sodium; CGP 19835 sodium|cas:90825-43-7|西域试剂

Mifamurtide sodium 米伐木肽钠盐; MTP-PE sodium; L-MTP-PE sodium; CGP 19835 sodium,98.0%

产品编号：Bellancom-13682B| CAS NO：90825-43-7| 分子式：C₅₉H₁₀₈N₆NaO₁₉P| 分子量：1259.48

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-13682B		￥6000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Mifamurtide sodium 米伐木肽钠盐; MTP-PE sodium; L-MTP-PE sodium; CGP 19835 sodium

产品介绍

Mifamurtide sodium (MTP-PE sodium) 是穆拉基二肽 (MDP) 的类似物，一种非特异性免疫调节剂，通过刺激激活巨噬细胞和单核细胞的免疫应答而发挥作用。Mifamurtide sodium 是一种孤儿药，是 NOD2 的特异性配体，用作胰岛素增敏剂。Mifamurtide sodium 具有用于骨肉瘤研究的潜力。

生物活性

Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium, an orphan agent, is a specific ligand of NOD2 used as an insulin sensitizer. Mifamurtide sodium has the potential for osteosarcoma research.

体外研究

Mifamurtide sodium (MTP-PE sodium; 100 µM) induces a reduction of MG63 cells number when co-cultured with macrophages.
Mifamurtide sodium (100 µM) increases both the M1 polarization marker iNOS and the M2 polarization marker CD206 mRNAs; both pro-inflammatory (IL-1β, IL-6) and anti-inflammatory (IL-4, IL-10) cytokines. Mifamurtide sodium increases the iron transporter DMT1 protein.
L-mifamurtide sodium (5, 5000 nM; for 48 hours) alone has no direct effect on the proliferation rate of the two osteosarcoma cell lines MOS-J and KHOS in vitro or in vivo.
Mifamurtide sodium acts as a nonspecific immunomodulator by activating macrophages and monocytes related to the upregulation of tumoricidal activity and secretion of pro-inflammatory cytokines including tumor necrosis factor (TNF)-a, interleukin (IL)-1, IL-6, IL-8, IL-12, nitric oxide (NO), prostaglandin E2 (PGE2) and PGD2.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Mifamurtide sodium (MTP-PE sodium; 1 mg/kg; i.v.; twice per week for 4 weeks) causes a trend of diminished spontaneous lung metastasis dissemination.
Mifamurtide sodium (50 μg/mouse) improves glucose tolerance during endotoxemia in mice. Mifamurtide sodium (equivalent to 20 μg MDP; 4 times per week for 5 weeks) improves glucose tolerance in HFD-fed mice without altering body mass.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6, BALB/c mice with KHOS osteosarcoma cells
Dosage:	1 mg/kg
Administration:	IV; twice per week for 4 weeks
Result:	Caused a trend of diminished spontaneous lung metastasis dissemination in xenogeneic (KHOS) and syngeneic (MOS-J) models.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6, BALB/c mice with KHOS osteosarcoma cells
Dosage:	1 mg/kg
Administration:	IV; twice per week for 4 weeks
Result:	Caused a trend of diminished spontaneous lung metastasis dissemination in xenogeneic (KHOS) and syngeneic (MOS-J) models.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (39.70 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.7940 mL	3.9699 mL	7.9398 mL
5 mM	0.1588 mL	0.7940 mL	1.5880 mL
10 mM	0.0794 mL	0.3970 mL	0.7940 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 5 mg/mL (3.97 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (3.97 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 5 mg/mL (3.97 mM); Suspended solution; Need ultrasonic

此方案可获得 5 mg/mL (3.97 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 5 mg/mL (3.97 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (3.97 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。